Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERIS: Optimal Sequence of EGFR-inhibitors in EGFR-mutated Lung Cancer
NCT06486142Phase 3Recruiting
- Sponsor
- Region Skåne
- Start
- Sep 2022
- Primary completion
- Sep 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib, afatinib, dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Region Skåne. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06486142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06486142.